Revolution Medicines officer plans $18.8M stock sale

Officer Stephen Kelsey has filed a Rule 144 notice to sell up to 92,531 RVMD shares acquired through stock option exercises.

Rhea-AI Filing Summary

Revolution Medicines, Inc. (RVMD) shareholder and officer Stephen Kelsey filed a notice of proposed sales of common stock under Rule 144. The notice covers up to 92,531 shares of RVMD common stock, with an indicated aggregate market value of $18,816,178.85, to be sold beginning on or about September 11, 2026 on NASDAQ.

The shares were and will be acquired through the exercise of stock options for cash over the next three months, with the dates of acquisition and payment matching the dates of exercise and sale. Kelsey also reported a prior sale of 4,175 shares on June 16, 2026.

Key Figures

Shares to be sold under Rule 144: 92,531 shares Aggregate market value of proposed sale: $18,816,178.85 RVMD shares outstanding: 214,336,418 shares +3 more

6 metrics

Shares to be sold under Rule 144 92,531 shares Proposed sale of RVMD common stock beginning on or about September 11, 2026

Aggregate market value of proposed sale $18,816,178.85 Value associated with 92,531 RVMD common shares to be sold

RVMD shares outstanding 214,336,418 shares Shares of Revolution Medicines, Inc. common stock outstanding as listed in the notice

Prior 3‑month shares sold 4,175 shares Shares of RVMD common stock sold by Stephen Kelsey on June 16, 2026

Aggregate value of prior sale $651,797.66 Aggregate amount for 4,175 RVMD shares sold on June 16, 2026

Planned sale start date September 11, 2026 Approximate date when sales of 92,531 shares may begin on NASDAQ

Key Terms

Rule 144, Exercise of Stock Options, Aggregate market value, securities to be sold

4 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Exercise of Stock Options financial

"Common | 09/11/2026 | Exercise of Stock Options | Issuer"

Aggregate market value financial

"Common | Morgan Stanley Smith Barney LLC ... | 92531 | 18816178.85"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

securities to be sold financial

"The securities to be sold were and will be received upon the exercise"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many RVMD shares does Stephen Kelsey plan to sell under this Form 144?

Stephen Kelsey plans to sell up to 92,531 shares of Revolution Medicines, Inc. common stock under Rule 144, with sales expected to begin on or about September 11, 2026 on NASDAQ, according to the notice.

What is the aggregate market value of the RVMD shares covered by this Form 144?

The Form 144 states an aggregate market value of $18,816,178.85 for the 92,531 shares of Revolution Medicines, Inc. common stock proposed to be sold.

How will Stephen Kelsey acquire the RVMD shares he plans to sell?

The notice states that the securities to be sold were and will be received upon the exercise of stock options, with payment in cash. The dates of acquisition and payment will be the dates of exercise and sale over the next three months.

Were any RVMD shares sold by Stephen Kelsey in the past three months?

Yes. The filing reports that Stephen Kelsey sold 4,175 shares of Revolution Medicines, Inc. common stock on June 16, 2026 for an aggregate amount of $651,797.66 during the past three months.

How many RVMD shares are outstanding according to the Form 144?

The Form 144 lists 214,336,418 shares of Revolution Medicines, Inc. common stock as outstanding, providing a context for the size of the proposed 92,531-share sale.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/11/2026 - 04:32 PM Accepted by SEC EDGAR 09/11/2026 - 04:32 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001462808
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Revolution Medicines, Inc.
SEC File Number	001-39219
Address of Issuer	700 Saginaw Drive Redwood City CALIFORNIA 94063
Phone	6504816801
Name of Person for Whose Account the Securities are To Be Sold	STEPHEN KELSEY
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	92531	18816178.85	214336418	09/11/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/11/2026	Exercise of Stock Options	Issuer			92531	09/11/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
STEPHEN KELSEY 700 Saginaw Drive Redwood City CA 94063	Common	06/16/2026	4175	651797.66

144: Remarks and Signature

Remarks	The securities to be sold were and will be received upon the exercise of stock options over the next three months. The dates of acquisition and payment were and will be the dates of exercise/sale.
Date of Notice	09/11/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	06/12/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Stephen Kelsey
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)